Scholar Rock (SRRK) Statistics & Alternative Data 2024

Q: How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025.

Q: Can scholar rock raise $42 million?

Scholar Rock has also granted underwriters a 30-day option to purchase up to 1.5 million shares of stock at the public offering price, which could raise $42 million more.

Q: Is scholar rock a good investment?

Make no mistake, however, Scholar Rock is currently valued as if its lead asset will be approved, and achieve at least $500m revenues per annum by 2030, in my view. Financially speaking, the company reported a net loss of $ (180m) year-to-date as of the end of Q3, up from $ (120m) in the prior year, and reported only $139m of cash.

Q: What challenges does scholar rock face?

Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025.

Dec 5, 2024 · Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High December 23 - SeekingAlpha: State Street Corp Sells 35,408 Shares of Scholar …

300%
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

2 weeks from now

Oct 9, 2024 · Shares of Scholar Rock soared more than 300% after the biotech’s data release, and the company seized on the opportunity to raise money. Late Tuesday, Scholar Rock …

medcitynews.com

$324
OFF

Scholar Rock: Good Company, But This Ship Has Sailed

2 weeks from now

Dec 24, 2024 · I covered Scholar Rock (NASDAQ:SRRK) ... Based on this data, Scholar Rock plans to submit an NDA in Q1 2025. ... including the approximately $324.4 million raised in the …

seekingalpha.com

$139
OFF

Scholar Rock Reports Third Quarter 2024 Financial Results And ...

2 weeks from now

Nov 12, 2024 · As of September 30, 2024, Scholar Rock had cash, cash equivalents and marketable securities of approximately $139.1 million ($463.5 million, on a pro forma basis, …

businesswire.com

364%
OFF

Here's Why Everybody's Talking About Scholar Rock Right Now

2 weeks from now

Oct 9, 2024 · Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage …

nasdaq.com

FAQs about Scholar Rock (SRRK) Statistics & Alternative Data 2024 Coupon?

Is scholar rock (SRRK) a missed investment opportunity?

Financially, Scholar Rock is well-positioned with a market cap of $4.19bn and a cash runway extending past initial approval timelines. Despite strong trial results, the current high valuation makes SRRK a missed investment opportunity; I'll observe from the sidelines. ...

Should you buy Scholar Rock stock in 2025?

If early in 2025, Scholar Rock stock has drifted to, let's say <$30 per share (its price does tend to dip quickly after rapid gains), the reward may be considered worth the risk of buying stock and risking an approval setback or a Phase 2 obesity failure. ...

How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. ...

Can scholar rock raise $42 million?

Scholar Rock has also granted underwriters a 30-day option to purchase up to 1.5 million shares of stock at the public offering price, which could raise $42 million more. ...

Is scholar rock a good investment?

Make no mistake, however, Scholar Rock is currently valued as if its lead asset will be approved, and achieve at least $500m revenues per annum by 2030, in my view. Financially speaking, the company reported a net loss of $ (180m) year-to-date as of the end of Q3, up from $ (120m) in the prior year, and reported only $139m of cash. ...

What challenges does scholar rock face?

Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. ...